Truist Securities analyst Asthika Goonewardene upgraded Gilead Sciences (NASDAQ: GILD) from Hold to Buy with a price target of $127.00 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE